SCHEMBL24257597

SCHEMBL24257597

CCOC(=O)CNC(=O)c1ncc(O)c(C)c1O

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.47
LMNA P02545 1/20 0.47
HPGD P15428 1/20 0.47
HSD17B10 Q99714 1/20 0.47
EGLN1 Q9GZT9 10/20 0.46
VEGFA P15692 4/20 0.46
FLT1 P17948 4/20 0.46
EGLN3 Q9H6Z9 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.45
MAPT P10636 1/20 0.44
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
PPID Q08752 2/20 0.42
PPIB P23284 1/20 0.40
PPIA P62937 1/20 0.40
PPIG Q13427 1/20 0.40
TP53 P04637 1/20 0.40
GLA P06280 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26260136 0.89 SMN1; SMN2 (0.45) ALDH1A1LMNAHPGDHSD17B10EGLN1
SCHEMBL24257725 0.86 ALDH1A1 (0.43) ALDH1A1LMNAHPGDHSD17B10EGLN1
SCHEMBL24257811 0.84 ALDH1A1 (0.41) ALDH1A1LMNAHPGDHSD17B10EGLN1
SCHEMBL26263986 0.82 EGLN1 (0.44) ALDH1A1LMNAHPGDHSD17B10EGLN1
SCHEMBL24257631 0.81 PPID (0.47) ALDH1A1LMNAHPGDHSD17B10EGLN1
SCHEMBL14150648 0.81 EGLN1 (0.55) ALDH1A1EGLN1VEGFAFLT1EGLN3
SCHEMBL30453195 0.80 CASP1 (0.49) ALDH1A1LMNAHPGDHSD17B10EGLN1
SCHEMBL24257534 0.80 CASP1 (0.49) ALDH1A1LMNAHPGDHSD17B10EGLN1
SCHEMBL24257727 0.80 ALDH1A1 (0.47) ALDH1A1LMNAHPGDHSD17B10EGLN1
SCHEMBL24257569 0.80 EGLN1 (0.48) ALDH1A1HPGDEGLN1RAB9APPID

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 ALDH1A1 1362/4885LMNA 4120/4885HPGD 109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.